4//SEC Filing
Skvarka Jan 4
Accession 0001725160-23-000162
CIK 0001725160other
Filed
Sep 12, 8:00 PM ET
Accepted
Sep 13, 4:11 PM ET
Size
5.2 KB
Accession
0001725160-23-000162
Insider Transaction Report
Form 4
Skvarka Jan
Director
Transactions
- Sale
Common Stock
2023-09-11$25.05/sh−5,000$125,238→ 47,970 total
Footnotes (2)
- [F1]The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires September 14, 2023.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.76 to $25.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Zentalis Pharmaceuticals, Inc.
CIK 0001725160
Entity typeother
Related Parties
1- filerCIK 0001838042
Filing Metadata
- Form type
- 4
- Filed
- Sep 12, 8:00 PM ET
- Accepted
- Sep 13, 4:11 PM ET
- Size
- 5.2 KB